Journal article

Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)

Rebecca Hein, Melanie Maranian, John L Hopper, Miroslaw K Kapuscinski, Melissa C Southey, Daniel J Park, Marjanka K Schmidt, Annegien Broeks, Frans BL Hogervorst, H Bas Bueno-de-Mesquit, Kenneth R Muir, Artitaya Lophatananon, Suthee Rattanamongkongul, Puttisak Puttawibul, Peter A Fasching, Alexander Hein, Arif B Ekici, Matthias W Beckmann, Olivia Fletcher, Nichola Johnson Show all

PLOS ONE | PUBLIC LIBRARY SCIENCE | Published : 2012

Grants

Awarded by European Community


Awarded by Cancer Research-UK


Awarded by European Union


Awarded by United States National Cancer Institute, National Institutes of Health (NIH)


Awarded by Dutch Cancer Society


Awarded by Fondo de Investigacion Sanitario


Awarded by National Institutes of Health


Awarded by Lon V Smith Foundation


Awarded by California Breast Cancer Research Fund


Awarded by California Department of Public Health


Awarded by Cancer Research UK


Awarded by US Military Acquisition (ACQ) Activity, Era of Hope Award


Awarded by Deutsche Krebshilfe


Awarded by Deutsche Krebshilfe e.V.


Awarded by German Research Foundation [DFG]


Awarded by Helsinki University Central Hospital Research Fund, Academy of Finland


Awarded by German Federal Ministry of Research and Education


Awarded by NHMRC


Awarded by United States Army Medical Research and Materiel Command


Awarded by Stichting tegen Kanker


Awarded by Federal Ministry of Education and Research (BMBF) Germany


Awarded by Ministero dell'Universita e Ricerca


Awarded by Associazione Italiana per la Ricerca sul Cancro


Awarded by Fondazione IRCCS Istituto Nazionale Tumori


Awarded by Specialized Program of Research Excellence (SPORE) in Breast Cancer


Awarded by Australian National Health and Medical Research Council (NHMRC)


Awarded by Norwegian Research council


Awarded by National Cancer Institute, National Institutes of Health [RFA]


Awarded by University of Melbourne


Awarded by Ministry of Health and Welfare, Republic of Korea


Awarded by National Institute of Health


Awarded by Massachusetts center


Awarded by Wisconsin center


Awarded by New Hampshire center



Awarded by National Institute for Health Research


Awarded by The Francis Crick Institute


Awarded by NATIONAL CANCER INSTITUTE


Funding Acknowledgements

This work was partly supported by the European Community's Seventh Framework Programme (COGS; http://cogseu.org/) [grant agreement number 223175, grant number HEALTH-F2-2009-223175]. The Breast Cancer Association Consortium (BCAC) is funded by Cancer Research-UK (http://science.cancerresearchuk.org/) [C1287/A10118 and C1287/A12014]. Meetings of the BCAC have been funded by the European Union COST programme (http://www.srl.cam.ac.uk/consortia/cost/index.html) [BM0606]. D. F. E. is a Principal Research Fellow of Cancer Research-UK. A. C. A. is a Cancer Research-UK Senior Cancer Research Fellow. A. M. D has been funded by Cancer Research-UK [C8197/A10865] and The Joseph Mitchell Trust. The Australian Breast Cancer Family Study (ABCFS) and Northern California Breast Cancer Family Registry (NC-BCFR) work was supported by the United States National Cancer Institute, National Institutes of Health (NIH) [RFA-CA-06-503]; and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR); and Principal Investigators, including Cancer Care Ontario [U01 CA69467]; Northern California Cancer Center [U01 CA69417]; University of Melbourne [U01 CA69638]. Samples from the NC-BCFR were processed and distributed by the Coriell Institute for Medical Research. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the U. S. Government or the BCFR. The ABCFS was also supported by the National Health and Medical Research Council of Australia; the New South Wales Cancer Council; the Victorian Health Promotion Foundation (Australia); and the Victorian Breast Cancer Research Consortium. J.L.H. is a National Health and Medical Research Council (NHMRC) Australia Fellow and a Victorian Breast Cancer Research Consortium Group Leader. M. C. S. is a NHMRC Senior Research Fellow and a Victorian Breast Cancer Research Consortium Group Leader. The Amsterdam Breast Cancer Study (ABCS) study was supported by the Dutch Cancer Society [NKI 2001-2423; 2007-3839]; and the Dutch National Genomics Initiative. The Asian Cancer Program (ACP) study was supported by the Breast Cancer Research Trust. The Bavarian Breast Cancer Cases and Controls (BBCC) study was partly supported by ELAN-Fond of the University Hospital of Erlangen. The British Breast Cancer Study (BBCS) study is supported by Cancer Research UK; and Breakthrough Breast Cancer; and acknowledges National Health Service (NHS) funding to the National Institute for Health Research (NIHR) Biomedical Research Centre; and the National Cancer Research Network (NCRN). Breast Cancer in Galway Genetic Study (BIGGS) is supported by National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre [to E. S.]; Guy's & St. Thomas' National Health Service Foundation Trust in partnership with King's College London [to E. S.]; and the Oxford Biomedical Research Centre [to I. T.]. The Breast Cancer Study of the University Clinic Heidelberg (BSUCH) study was supported by the Dietmar-Hopp Foundation; and the Helmholtz Society. The CECILE Breast Cancer Study (CECILE) study was supported by Fondation de France (2007), French National Institute of Cancer [INCa grant 2007, 2008, 2009]; French Agency for Environmental and Occupational Health [ANSES (ex-AFSSET) grant 2008 and 2009]; the French League Against Cancer; and National Research Agency (ANR).The Copenhagen General Population Study (CGPS) was supported by the Chief Physician Johan Boserup and Lise Boserup Fund; the Danish Medical Research Council; and Herlev Hospital. The Spanish National Cancer Centre Breast Cancer Study (CNIO-BCS) was supported by the Genome Spain Foundation; the Red Tematica de Investigacion Cooperativa en Cancer and grants from the Asociacion Espanola Contra el Cancer and the Fondo de Investigacion Sanitario [PI081120 to J.B., PI081583 to R. L. M.]. The California Teachers Study (CTS) was supported by the California Breast Cancer Act of 1993; National Institutes of Health [R01 CA77398]; the Lon V Smith Foundation [LVS39420]; and the California Breast Cancer Research Fund [contract 97-10500]. Collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. The ESTHER Breast Cancer Study (ESTHER) study was supported by a grant from the Baden Wurttemberg Ministry of Science, Research and Arts. Additional cases were recruited in the context of the VERDI study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). The ICR Familial Breast Cancer Study (FBCS) is supported by funds from Cancer Research UK [C8620/A8372; C8620/A8857]; a US Military Acquisition (ACQ) Activity, Era of Hope Award [W81XWH-05-1-0204]; the Institute of Cancer Research (UK) a Medical Research Council (UK) Clinical Research Fellowship [to C. T.]. The FBCS acknowledges National Health Service (NHS) funding to the Royal Marsden/Institute of Cancer Research, National Institute for Health Research (NIHR) Specialist Cancer. The German Consortium for Hereditary Breast & Ovarian Cancer (GC-HBOC) was supported by Deutsche Krebshilfe [107054]; the Center of Molecular Medicine, Cologne; the Helmholtz society; and the Dietmar Hopp Foundation [to B. B.]. The Gene Environment Interaction and Breast Cancer in Germany (GENICA) network was supported by the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and the University of Tubingen, Germany [to C.J. and H. B.]; the Department of Internal Medicine, Evangelische Kliniken Bonn GmbH, Johanniter Krankenhaus, Bonn, Germany [to Y.D.K. and C.B.]; the Institute of Pathology, University of Bonn, Bonn, Germany [to HP. F.]; Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany [to U. H.]; the Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, Germany [to T. B., B. P., S. R., A. S. and V. H.]. The Genetic Epidemiology Study of Breast Cancer by Age 50 (GESBC) was supported by the Deutsche Krebshilfe e.V. [70492]; and genotyping in part by the state of Baden-Wurttemberg through the Medical Faculty of the University of Ulm [P.685]. The Hannover Breast Cancer Study (HABCS) study was supported by an intramural grant from Hannover Medical School; and by a grant from the German Research Foundation [DFG, Do761/2-1]. The Helsinki Breast Cancer Study (HEBCS) study has been financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland [132473]; the Finnish Cancer Society; and the Sigrid Juselius Foundation. The Hannover-Minsk Breast Cancer Study (HMBCS) was supported by short-term fellowships from the German Academic Exchange Program [to N.B.]; and the Friends of Hannover Medical School [to N.B.].The Hannover-Ufa Breast Cancer Study (HUBCS) was supported by a grant from the German Federal Ministry of Research and Education [RUS08/017]. The Karolinska Breast Cancer Study (KARBAC) was supported by the Swedish Cancer Society and the Stockholm Cancer Society. The Kuopio Breast Cancer Project (KBCP) was financially supported by the special Government Funding (EVO) of Kuopio University Hospital grants, Cancer Fund of North Savo; the Finnish Cancer Organizations; the Academy of Finland; and by the strategic funding of the University of Eastern Finland. Kathleen Cuningham Foundation Consortium for research into Familial Breast Cancer/Australian Ovarian Cancer Study (KConFab/AOCS) is supported by grants from the National Breast Cancer Foundation; the National Health and Medical Research Council (NHMRC); the Queensland Cancer Fund; the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia; and the Cancer Foundation of Western Australia. The kConFab Clinical Follow Up Study was funded by the NHMRC [145684; 288704; 454508]. Financial support for the AOCS was provided by the United States Army Medical Research and Materiel Command [DAMD17-01-1-0729]; the Cancer Council of Tasmania and Cancer Foundation of Western Australia; and the NHMRC [199600]. G. C. T. and P. W. are supported by the NHMRC. Leuven Multidisciplinary Breast Centre (LMBC) is supported by the 'Stichting tegen Kanker' [232-2008; 196-2010]. The Mammary Carcinoma Risk Factor Investigation (MARIE) study was supported by the Deutsche Krebshilfe e.V. [70-2892-BR I]; the Hamburg Cancer Society; the German Cancer Research Center; and the genotype work in part by the Federal Ministry of Education and Research (BMBF) Germany [01KH0402]. Milan Breast Cancer Study Group (MBCSG) was supported by grants from Ministero della Salute (Extraordinary National Cancer Program 2006 "Alleanza contro il Cancro", and "Progetto Tumori Femminili") [to P. R.]; Ministero dell'Universita e Ricerca (RBLAO3-BETH) [to P. R.]; Fondazione Italiana per la Ricerca sul Cancro (Special Project "Hereditary tumors"); Associazione Italiana per la Ricerca sul Cancro (4017) [to P. P.]; and by funds from Italian citizens who allocated the 5/1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects "561000"). The Mayo Clinic Breast Cancer Study (MCBCS) was supported by National Institutes of Health grants [R01CA122340; R01 CA128978]; and a Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201]. Melbourne Collaborative Cohort Study (MCCS) cohort recruitment was funded by VicHealth; and Cancer Council Victoria. The MCCS was further supported by Australian National Health and Medical Research Council (NHMRC) grants [209057; 251553; 504711]; and by infrastructure provided by Cancer Council Victoria. The Memorial Sloan-Kettering Cancer Center (MSKCC) was supported by the Breast Cancer Research Foundation; the Sharon Levine Corzine Fund; the Niehaus Cancer Research Initiative; the Andrew Sabin Family Fund; the Charles Krasne Research Fund; and the Norman and Carol Stone Research Initiative. The Norwegian Breast Cancer Study (NBCS) was supported by grants from the Norwegian Research council [155218/V40, 175240/S10 to A. L. B. D.; FUGE-NFR 181600/V11 to V.N.K.]; and a Swizz Bridge Award [to A. L. B. D.].The Oulu Breast Cancer Study (OBCS) was supported by research grants from the Finnish Cancer Foundation; the Sigrid Juselius Foundation; the Academy of Finland; the University of Oulu; and the Oulu University Hospital. The Ontario Familial Breast Cancer Registry (OFBCR) work was supported by the National Cancer Institute, National Institutes of Health [RFA # CA-06-503]; and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR); and Principal Investigators, including Cancer Care Ontario [U01 CA69467]; Northern California Cancer Center [U01 CA69417]; and University of Melbourne [U01 CA69638]; and by Cancer Care Ontario. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the U. S. Government or the BCFR. The National Cancer Institute Polish Breast Cancer Study (PBCS) was supported by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. The Rotterdam Breast Cancer Study (RBCS) was funded by the Dutch Cancer Society [DDHK 2004-3124; DDHK 2009-4318]. The Singapore and Sweden Breast Cancer Study (SASBAC) was funded by the Marit and Hans Rausing Initiative Against Breast Cancer; the Agency for Science, Technology and Research of Singapore (ASTAR); the United States National Institutes of Health (NIH); and the Susan G. Komen Breast Cancer Foundation. The Sheffield Breast Cancer Study (SBCS) was funded by Yorkshire Cancer Research; and the Breast Cancer Campaign. The Study of Epidemiology and Risk factors in Cancer Heredity (SEARCH) study is funded by a programme grant from Cancer Research UK [C490/A11021] and laboratory infrastructure by [C8197/A10123]. The Seoul Breast Cancer Study (SEBCS) was supported by the Korea Health 21 R&D Project [AO30001], Ministry of Health and Welfare, Republic of Korea. The IHCC-Szczecin Breast Cancer Study (SZBCS) was supported by Grant PBZ_KBN_122/P05/2004; and the Polish Foundation of Science [to K.J.]. Katarzyna Jaworska is a fellow of International PhD program, Postgraduate School of Molecular Medicine, Warsaw Medical University. The International Agency for Research on Cancer-Thai Breast Cancer Study (TBCS) was funded by The National Cancer Institute Thailand. The Taiwanese Breast Cancer Study (TWBCS) is supported by the Taiwan Biobank project of the Institute of Biomedical Sciences, Academia Sinica, Taiwan. The University of California, Irvine, Breast Cancer Study (UCIBCS) component of this research was supported by the National Institute of Health [CA58860; CA92044]; and the Lon V Smith Foundation [LVS39420]. The UK Breakthrough Generations Study (UKBGS) is funded by Breakthrough Breast Cancer. The US Three State Study (US3SS) study was supported by Massachusetts [R01CA47305 to K. M. E.]; Wisconsin [R01 CA47147 to P.A.N.]; and New Hampshire [R01CA69664 to L. T.-E.] centers; and Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.